Cystic fibrosis: Physiopathology and the latest pharmacological treatments

Bardin, 2018, Emerging microRNA therapeutic approaches for cystic fibrosis, Front. Pharmacol., 9, 1113, 10.3389/fphar.2018.01113 Sockrider, 2017, Twenty facts about cystic fibrosis, Am. J. Respir. Crit. Care Med., 196, 23, 10.1164/rccm.19612P23 Seegmiller, 2014, Abnormal unsaturated fatty acid metabolism in cystic fibrosis: biochemical mechanisms and clinical implications, Int. J. Mol. Sci., 15, 16083, 10.3390/ijms150916083 Rafeeq, 2017, Cystic fibrosis: current therapeutic targets and future approaches, J. Transl. Med., 15, 84, 10.1186/s12967-017-1193-9 Hwang, 2018, Structural mechanisms of CFTR function and dysfunction, J. Gen. Physiol., 150, 539, 10.1085/jgp.201711946 De Boeck, 2016, Progress in therapies for cystic fibrosis, Lancet Respir. Med., 4, 662, 10.1016/S2213-2600(16)00023-0 Bardin, 2018, Small RNA and transcriptome sequencing reveal the role of miR-199a-3p in inflammatory processes in cystic fibrosis airways, J. Pathol., 245, 410, 10.1002/path.5095 Le, 2018, Updates in vitamin D therapy in cystic fibrosis, Curr. Opin. Endocrinol. Diabetes Obes., 25, 361, 10.1097/MED.0000000000000439 Ronan, 2017, Current and emerging cormobidities in cystic fibrosis, La Presse Médicale, 46, e125, 10.1016/j.lpm.2017.05.011 Fajac, 2017, New treatments targeting the basic defects in cystic fibrosis, La Presse Médicale, 46, e165, 10.1016/j.lpm.2017.01.024 Elborn, 2016, Cystic fibrosis, Lancet, 388, 2519, 10.1016/S0140-6736(16)00576-6 Burgel, 2015, Future trends in cystic fibrosis demography in 34 European countries, Eur. Respir. J., 46, 133, 10.1183/09031936.00196314 Jain, 2020, Triple therapy for cystic fibrosis with a Phe508del CFTR mutation, N. Engl. J. Med., 382, 684, 10.1056/NEJMc1916747 De Boeck, 2014, The relative frequency of CFTR mutation classes in European patients with cystic fibrosis, J. Cyst. Fibros., 13, 403, 10.1016/j.jcf.2013.12.003 Carter, 2016, Pharmacogenetics of cystic fibrosis treatment, Pharmacogenomics, 17, 1453, 10.2217/pgs.16.25 Borowitz, 2015, CFTR, bicarbonate, and the pathophysiology of cystic fibrosis, Pediatr. Pulmonol., 50, S24, 10.1002/ppul.23247 Saint-Criq, 2017, Role of CFTR in epithelial physiology, Cell. Mol. Life Sci., 74, 93, 10.1007/s00018-016-2391-y Jun, 2016, Pore dilatation increases the bicarbonate permeability of CFTR, ANO1 and glycine receptor anion channels, J. Physiol., 594, 2929, 10.1113/JP271311 Bodas, 2019, Adapting proteostasis and autophagy for controlling the pathogenesis of cystic fibrosis lung disease, Front. Pharmacol., 10, 1 Strub, 2020, Transcriptomic and proteostasis networks of CFTR and the development of small molecule modulators for the treatment of cystic fibrosis lung disease, Genes, 11, 1, 10.3390/genes11050546 Kunzelmann, 2013, CFTR: a hub for kinase and crosstalk of cAMP and Ca2+, FEBS J., 280, 4417, 10.1111/febs.12457 Hansen, 2011, Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection, ISME J., 6, 31, 10.1038/ismej.2011.83 Flume, 2005, Massive hemoptysis in cystic fibrosis, Chest, 128, 729, 10.1378/chest.128.2.729 Flume, 2005, Pneumothorax in cystic fibrosis, Chest, 128, 720, 10.1378/chest.128.2.720 Houwen, 2010, Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS, J. Pediatr. Gastroenterol. Nutr., 50, 38, 10.1097/MPG.0b013e3181a6e01d Umunakwe, 2014, Abnormal n-6 fatty acid metabolism in cystic fibrosis is caused by activation of AMP-activated protein kinase, J. Lipid Res., 55, 1489, 10.1194/jlr.M050369 Ahmad, 2013, Cystic fibrosis and fertility, Curr. Opin. Obstet. Gynecol., 25, 167, 10.1097/GCO.0b013e32835f1745 Lommatzsch, 2019, The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy, Ther. Adv. Respir. Dis., 13, 1, 10.1177/1753466619844424 Mathiesen, 2018, Osteoporosis Is Associated with Deteriorating Clinical Status in Adults with Cystic Fibrosis, Int. J. Endocrinol., 2018, 1, 10.1155/2018/4803974 Cystic Fibrosis Foundation, 2019 Levy, 2015, New challenges in the diagnosis and management of cystic fibrosis, J. Pediatr., 166, 1337, 10.1016/j.jpeds.2015.03.042 Bell, 2015, New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls, Pharmacol. Ther., 145, 19, 10.1016/j.pharmthera.2014.06.005 Wojewodka, 2014, Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients, PLoS One, 9, 10.1371/journal.pone.0088567 Farrel, 2017, Cystic fibrosis diagnostic challenges over 4 decades: historical perspectives and lessons learned, J. Pediatr., 181, 16, 10.1016/j.jpeds.2016.09.067 Farrell, 2017, Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation, J. Pediatr., 181, 10.1016/j.jpeds.2008.05.005 Burgener, 2018, Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis, Curr. Opin. Pediatr., 30, 372, 10.1097/MOP.0000000000000627 Flume, 2012, Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation, Chest, 142, 718, 10.1378/chest.11-2672 Clancy, 2012, Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation, Thorax, 67, 12, 10.1136/thoraxjnl-2011-200393 Sala, 2018, Tezacaftor for the treatment of cystic fibrosis, Expert Rev. Respir. Med., 1 Boyle, 2014, A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial, Lancet Respir. Med., 2, 527, 10.1016/S2213-2600(14)70132-8 Skov, 2019, Cystic fibrosis - an example of personalized and precision medicine, APMIS, 127, 352, 10.1111/apm.12915 Wainwright, 2015, Lumacaftor–Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR, N. Engl. J. Med., 373, 220, 10.1056/NEJMoa1409547 Tsai, 2020, Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from Mono or dual regimens to triple-combination Elexacaftor/Tezacaftor/Ivacaftor, Pulm. Ther. Altamura, 2013, Tobramycin is a suppressor of premature termination codons, J. Cyst. Fibros., 12, 806, 10.1016/j.jcf.2013.02.007 Tosco, 2016, A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR, Cell Death Differ., 23, 1380, 10.1038/cdd.2016.22 Hanrahan, 2019, Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets, Expert Opin. Ther. Targets, 23, 711, 10.1080/14728222.2019.1628948 Hart, 2017, Genetic therapies for cystic fibrosis lung disease, Curr. Opin. Pharmacol., 34, 119, 10.1016/j.coph.2017.10.006 Glasgow, 2018, Non-coding RNA in cystic fibrosis, Biochem. Soc. Trans., 46, 619, 10.1042/BST20170469 Alton, 2015, Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial, Lancet, 3, 684 Mastorakos, 2015, Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy, Proc. Natl. Acad. Sci., 112, 8720, 10.1073/pnas.1502281112 Amato, 2013, Gene mutation in MicroRNA target sites of cftr gene: a novel pathogenetic mechanism in cystic fibrosis?, PLoS One, 8, 10.1371/journal.pone.0060448 Viart, 2014, Transcription factors and miRNAs that regulate fetal to adult CFTR expression change are new targets for cystic fibrosis, Eur. Respir. J., 45, 116, 10.1183/09031936.00113214 Ramachandran, 2012, A microRNA network regulates expression and biosynthesis of wild-type and F508 mutant cystic fibrosis transmembrane conductance regulator, Proc. Natl. Acad. Sci., 109, 13362, 10.1073/pnas.1210906109 Tazi, 2016, Elevated Mirc1/Mir17-92 cluster expression negatively regulates autophagy and CFTR (cystic fibrosis transmembrane conductance regulator) function in CF macrophages, Autophagy, 12, 2026, 10.1080/15548627.2016.1217370 Ramachandran, 2013, Post-transcriptional regulation of cystic fibrosis transmembrane conductance regulator expression and function by MicroRNAs, Am. J. Respir. Cell Mol. Biol., 49, 544, 10.1165/rcmb.2012-0430OC Weldon, 2014, miR-31 dysregulation in cystic fibrosis airways contributes to increased pulmonary cathepsin S production, Am. J. Respir. Crit. Care Med., 190, 165, 10.1164/rccm.201311-1986OC Zhang, 2015, Pharmacological modulation of the AKT/microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation, Nat. Commun., 6 Bhattacharyya, 2011, Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of Interleukin-8, J. Biol. Chem., 286, 11604, 10.1074/jbc.M110.198390 Chevalier, 2015, miR-34/449 control apical actin network formation during multiciliogenesis through small GTPase pathways, Nat. Commun., 6, 1 Zhong, 2011, MiR-146a negatively regulates neutrophil elastase-induced MUC5AC secretion from 16HBE human bronchial epithelial cells, Mol. Cell. Biochem., 358, 249, 10.1007/s11010-011-0975-2 Oglesby, 2010, miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression, J. Immunol., 184, 1702, 10.4049/jimmunol.0902669 De Santi, 2020, Precise targeting of miRNA sites restores CFTR activity in CF bronchial epithelial cells, Mol. Ther., 28, 1190, 10.1016/j.ymthe.2020.02.001 Sonneville, 2017, MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology, Nat. Commun., 8, 10.1038/s41467-017-00813-z Gillen, 2011, microRNA regulation of expression of the cystic fibrosis transmembrane conductance regulator gene, Biochem. J., 438, 25, 10.1042/BJ20110672 Yeh, 2019, Structural mechanisms for defective CFTR gating caused by the Q1412X mutation, a severe Class VI pathogenic mutation in cystic fibrosis, J. Physiol. (Lond.), 597, 543, 10.1113/JP277042 Mogayzel, 2013, Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health, Am. J. Respir. Crit. Care Med., 187, 680, 10.1164/rccm.201207-1160OE Brown, 2017, Keep them breathing cystic fibrosis pathophysiology, diagnosis, and treatment, J. Am. Acad. Physician Assist., 30, 23, 10.1097/01.JAA.0000515540.36581.92 EMA, 2016 INFARMED, 2014 INFARMED, 2018 INFARMED, 2015 Schwarzenberg, 2019